Study objective: To determine whether ion transport or barrier function across the nasal epithelium are altered in asthmatics. Design: In this pilot study, the nasal potential difference (PD) was measured using the technique established by Knowles and colleagues. A flowing agar bridge made electrical contact with the surface of the nasal epithelium along the floor of the nose. This bridge was referenced to a cutaneous electrode to determine the PD across the nasal epithelium. Changes in nasal PD in response to amiloride, chloride-free medium, and chloride-free medium containing isoproterenol were measured, and responses of asthmatics and healthy control subjects were compared. Participants: Measurements were made in eight adult nonasthmatic subjects and 6 adult asthmatic subjects. All asthmatics had mild intermittent asthma. Measurements and results: Continuous measurements of nasal PD were obtained while the nasal surface was perfused consecutively with saline solution (NaCl-containing solution), saline solution plus 100 mol/L amiloride, chloride-free solution plus amiloride, and chloride-free solution with amiloride plus 10 mol/L isoproterenol (a ␤-adrenergic agonist). No significant differences in baseline PD or change in PD in response to changes in perfusate were found between the two groups. Conclusions: Our results suggest that ion transport and barrier function of patients with mild asthma are normal. Therefore, by contrast to cystic fibrosis, changes in salt and water transport across airway epithelium may not contribute to accumulation of mucous secretions in asthma.
A sthma is a clinical condition characterized by airflow obstruction secondary to bronchial smooth-muscle constriction, airway inflammation, and accumulation of mucous secretions. 1 Asthma also shares symptoms common to cystic fibrosis (CF), such as (allergic) rhinitis, wheezing, cough and, in particular, increased mucous secretions. The primary defect in CF is the dysfunction of an epithelial chloride channel that results in alterations of epithelial salt transport. 2 Owing to the partial overlap of the pathophysiology of asthma and CF, we hypothesized that, as in CF, patients with asthma have abnormalities in ion (and consequently water) transport across their surface respiratory epithelium.
Accumulation of airway mucous secretions in patients with CF may represent predominantly a defect in airway gland function. [3] [4] [5] The consequences of decreased apical membrane chloride conductance in airway surface epithelium are less clear. Nevertheless, there is general agreement that salt transport across airway surface epithelium does play a role in regulating the water content of mucous secretions. In so doing, it will influence the viscosity of the secretions and the rate at which they are cleared by cilia. Specifically, it has been proposed that elevation of active sodium absorption across airway epithelium in CF leads to excess water removal, and concentration of mucous secretions. This in turn inhibits mucociliary clearance and results in buildup of mucous secretions. 6 The measurement of the nasal potential difference (PD) provides information on the types of ion transport present in the airway epithelium. In particular, the use of nasal PD measurements has proved useful in the diagnosis of patients with CF who have suspicious clinical histories but equivocal laboratory data or who do not have a genetic mutation known to produce CF. [7] [8] [9] The measurement is based on the principal defect in the epithelial chloride conductance, and secondary changes in sodium transport. Thus, baseline PD is elevated in patients with CF due to an increase in active sodium absorption, and the depolarization induced by block of active sodium absorption with amiloride is also correspondingly increased. In normal subjects, the presence of the CF transmembrane conductance regulator (CFTR), a cyclic adenosine monophosphate (cAMP)-activated chloride channel in the apical membrane of nasal epithelium, 10 causes the nasal PD to hyperpolarize on perfusion of the nasal surface with chloride-free medium, and this hyperpolarization is increased still further by superfusion of cAMP-elevating agents. By contrast, neither chloride-free medium nor elevation of cAMP affect the nasal PD in patients with CF. 9 Nasal PD is measured on the inferior surface of the inferior turbinate. 9 The mucosa at this site is histologically and functionally similar to the mucosa of the upper airways. 11, 12 In addition, it has been shown that rhinitis and asthma are associated, and both may represent different aspects of the same underlying pathology. [13] [14] [15] Furthermore, the nasal mucosa has proven a useful and easily accessible site to evaluate mucous secretion by goblet cells and submucosal cells, 16 allergen-induced changes of mucosal secretory and barrier functions, 17, 18 composition of airway surface liquid and pH, 19, 20 and mucociliary clearance. 21 To determine whether changes in ion transport or barrier function of the airway epithelium contribute to the pathophysiology of asthma, we have compared nasal PDs of asthmatics and healthy control subjects.
Materials and Methods

Subjects
Nasal PD measurements were made in 15 volunteers (8 nonasthmatics, 6 asthmatics, and 1 patient with CF). There were five females and one male in the asthmatic group and four males and four females in the nonasthmatic group. The average ages of the control subjects and asthmatics were 38 Ϯ 3.5 years and 30.5 Ϯ 1.9 years (mean Ϯ SE), respectively. To validate our technique, we also studied one 17-year-old male subject with CF. The procedure was approved by the Institutional Review Board at Children's Hospital Oakland, and informed consent was obtained. All asthmatics had mild intermittent asthma and were either asymptomatic or had mild exacerbations. Two subjects in the asthmatic group and one subject in the control group suffered from allergic rhinitis requiring inhaled nasal steroids within 2 weeks of the measurements. Three asthmatics were being treated with prophylactic inhaled steroids for their asthma, including one of the two mentioned above who also required inhaled nasal steroids.
Measurement of Nasal PD
Our measuring technique 22 is based on those of others. 8, 9 In brief, as the exploring electrode we used a 10F Bardex Foley catheter (Bard; Murray Hill, NJ) with one of the two holes at the tip plugged with silicone. The proximal end of the Foley catheter was connected to a silver/silver chloride electrode via a 2 mol/L NaCl/3% agar bridge. The reference electrode was a selfadhesive ECG surface electrode (ConMed Corporation; Utica, NY) placed over an area of skin that had been lightly scratched to break the surface. The PD between the exploring and the skin electrode was measured with a high-impedance voltmeter (Keithley Instruments; Cleveland, OH). Prior to use, the electrodes were checked by placing the open tip of the Foley catheter in the gel of the skin electrode, and the measured electrode potential was zeroed. If the electrode potential was unstable or ϾϮ 5 millivolts (mV), the electrodes were replaced. PDs are reported as the voltage measured by the exploring electrode with respect to the skin electrode, which is usually a negative number. In the graphs, negative numbers are plotted upwards.
Initially, the subjects blew their noses. The exploring electrode was then advanced into the inferior nasal turbinate along the floor of the nose. The perfusate (20 to 22°C) ran continuously (at approximately 5 mL/min) through the exploring electrode, which was advanced until the maximal baseline PD was measured. The subject tilted his/her chin down to allow the perfusate to drain out of the nose. The initial saline solution was perfused for at least 5 min to wash off remaining nasal mucus. This solution contained 145 mmol/L NaCl, 1 mmol/L KCl, 1 mmol/L CaCl 2 , 1 mmol/L MgCl 2 , and 10 mmol/L hydroxylethyl piperazine-enthanesulfonic acid, pH 7.4 with NaOH. This was followed by the same saline solution with 100 mol/L amiloride added (Spectrum; New Brunswick, NJ). Next, the nasal surface was perfused with chloride-free medium containing 145 mmol/L sodium gluconate, 4 mmol/L K gluconate, 1 mmol/L Ca gluconate, and 1 mmol/L Mg gluconate, 10 mmol/L hydroxylethyl piperazine-enthanesulfonic acid, 0.1 mmol/L amiloride, pH 7.4 with NaOH. Final perfusion was with chloride-free solution containing amiloride and 10 mol/L isoproterenol (Spectrum) or isoproterenol injection (Isuprel; Abbott Laboratories; North Chicago, IL). Solution changes were made as soon as the PD in any given medium stabilized, generally at intervals of approximately 5 min. Groups were statistically compared using unpaired, two-tailed t tests. A probability of p Ͻ 0.05 was considered significant.
Results
Typical tracings of nasal PD recordings for normal subjects and asthmatic patients are shown in Figure 1 . In normal subjects (Fig 1, top left, A) , addition of amiloride blocked a large part of the nasal PD, and perfusion with chloride-free solution caused a hyperpolarization. Addition of isoproterenol further hyperpolarized nasal PD. For comparison, Figure 1 , top center, B shows a typical recording from an asthmatic subject. The measured responses to amiloride, chloride-free, and isoproterenol were qualitatively not different and similar in magnitude to normal subjects.
To test the reliability of the measurements, we performed a nasal PD measurement in a patient with CF (a 17-year-old male patient with genotype ⌬F508/ ⌬F508), which is shown for comparison in Figure 1 , top right, C (note the different y-axis scaling). The baseline PD (Ϫ 47 mV) of the tested patient with CF was greater than any of the asthmatic or control subjects, as was the decrease produced by amiloride (51 mV). Also, typical for CF were the absence of a hyperpolarization in nasal PD in chloride-free solution (ϩ 0.7 mV) or after addition of isoproterenol (Ϫ 1.2 mV). These values were similar to those reported previously in patients with CF. 9 Figure 1 , bottom left, D shows the average (Ϯ SE) PD values in the various solutions for asthmatics and normal control subjects. The two groups were not significantly different from one another. We also compared between the two groups the changes of nasal PD caused by solution changes. These were previously shown to be more sensitive indicators of ion conductances in the nasal epithelium. 9 The changes in nasal PD after changes in perfusate are shown in Figure 1 , bottom right, E. Again, there were no significant differences between asthmatics and control subjects. In the control group, PD values in male and female subjects were not different. In the asthmatic group, there were not enough male subjects to permit statistical comparison between genders. Inhaled nasal steroids (two of six asthmatics and one of eight control subjects) did not affect the magnitude of the readings nor did mild exacerbations of asthma (one of six asthmatics). 
Discussion
Measurements of nasal PD has been previously used to measure ion transport properties in normal subjects and patients with CF, 9, 23 which show largely different treatment responses so that the measurement of nasal PD is now frequently used as a diagnostic test for CF. 24 The major differences of patients with CF (compared to normal subjects) is the increased baseline PD, the increased amiloride response, and the lack of a significant effect of treatment with chloride-free solution and isoproterenol. In our study, we could reproduce these reported differences between normal subjects and patients with CF. However, no aspect of the measurements in asthmatics showed a significant difference to the measurements in control subjects, suggesting that the mild asthmatic subjects studied here showed no abnormalities in the ion conductances or the epithelial barrier of their nasal mucosa. Presumably, therefore, salt and water transport across the nasal epithelium are unaltered and do not contribute to the accumulation of mucous secretions. We speculate that the excess secretions seen in asthmatics are due to excess gland secretion by airway glands, organs that are hypertrophied in asthma. 25 Nasal PD is influenced by both active ion transport and the transepithelial electrical resistance of the nasal mucosa. Active absorption of sodium and secretion of chloride by the epithelium generate the PD, which then causes secondary current flow through epithelial leak pathways, which in the airway epithelium are predominantly in the paracellular route, ie, the tight junctions and the lateral intercellular spaces. These leak currents tend to depolarize the PD. In asthma with epithelial damage and compromised barrier function, it is conceivable that the paracellular pathway significantly affects the nasal PD measurements. However, in our study measurements in mild asthmatics and control subjects were similar, and the simplest interpretation is that both epithelial ion transport and barrier function were similar in both groups.
Rhinitis is frequently observed in asthmatics. Inflammatory mediators, such as tumor necrosis factor-␣ and nitric oxide, in turn, have been shown to affect both sodium and chloride transport by lung epithelia both in vitro and in vivo 26 -28 ; therefore, we predict that during epithelial inflammation the nasal PD reading will be changed. In our study, little or no acute inflammation was noted, either in the asthmatics or the control subject with rhinitis, possibly because we dealt with mild asthmatics. Therefore, in contrast to CF, our results support the hypothesis that mild asthmatics show no intrinsic changes in epithelial ion transport in their airways.
